Cite
HARVARD Citation
Economides, M. et al. (2019). Tagraxofusp, the first CD123-targeted therapy and first targeted treatment for blastic plasmacytoid dendritic cell neoplasm. Expert review of clinical pharmacology. 12 (10), pp. 941-946. [Online].